Form Approved

OMB No. 0920-0840

Expiration Date: 10/31/2021

Virtual Focus Groups with Primary Care Physicians and OBGYNs:
Attitudes about Proposed Hepatitis C Screening Guidelines
DVH 2019

Generic Information Collection under Formative Research and Tool Development OMB #0920-0840

**Attachment #7**

**Discussion Guide**

**Privacy Act Statement:**

This information is collected under the authority of the Public Health Service Act, Section 301, "Research and Investigation," (42 U.S.C. 241); and Sections 304, 306 and 308(d) which discuss authority to maintain data and provide assurances of confidentiality for health research and related activities (42 U.S.C. 242 b, k, and m(d)). This information is also being collected in conjunction with the provisions of the Government Paperwork Elimination Act and the Paperwork Reduction Act (PRA). This information will only be used by the Centers for Disease Control and Prevention (CDC) staff to inform activities of the Division of Viral Hepatitis (DVH).

Public reporting burden of this collection of information is estimated to average 90 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC/ATSDR Reports Clearance Officer; 1600 Clifton Road NE, MS D-74, Atlanta, Georgia 30333; Attn: OMB-PRA (0920-0840)

**DISCUSSION GUIDE
Virtual Focus Groups with Primary Care Physicians and OBGYNs:
Attitudes about Proposed Hepatitis C Screening Guidelines
DVH 2019**

**GUIDING RESEARCH QUESTIONS**

* What are physicians’ current attitudes on screening patients for hepatitis C?
* What are physicians’ reactions to CDC’s proposed universal hepatitis C screening recommendation?
* What are physicians’ reactions to CDC’s proposed prevalence-based hepatitis C screening recommendation?
* What are physicians’ reactions to CDC’s proposed hepatitis C screening recommendation for women during each pregnancy?
* What are physicians’ reactions to CDC’s proposed prevalence-based hepatitis C screening recommendation for women during each pregnancy?
* What are physicians’ reactions to the rationale behind CDC’s proposed screening recommendations?

**DISCUSSION GUIDE**

1. **Background (5 minutes)**
* My name is [INSERT]. I’m a researcher and independent moderator with KRC Research.
* Thank you for participating in today’s discussion. The discussion will be about 75 minutes. The purpose of our discussion is to learn your opinions and behaviors regarding certain screening tests and guidelines.
* The sole sponsor is CDC. Our discussion is for research purposes only. Because privacy is important, I’m going to take a moment to read our Privacy Policy.
**SHOW CONFIDENTIALITY LANGUAGE ON SCREEN, READ**:
* Your feedback is confidential—neither your name nor information that could be associated with you will be included in the final report.
* We will use first names only during the conversation.
* The discussion is being audio recorded so we have an accurate record. All audio files and transcripts will be secured.
* We ask that you not share any information, participant comments, or the identities of any participants in the focus group discussion with your colleagues, family or friends.
* May I please have a verbal agreement from everyone?
* To get started, let me explain how our discussion will work today:
	+ There are no wrong answers. You may have different opinions. That’s ok—we want to hear all of your opinions.
	+ We will be putting some information on your screen to look at and respond to. Each person only sees their own answers, but I can see everyone’s answers.
	+ Since we are having these groups online, we will need to talk one at a time and let everyone have time to speak.
	+ If at any time you can’t see the screen well or have difficulty hearing, let me know—I have a technician here who can help us with any technical issues.
	+ I am a researcher and a moderator, but I am not physician or an expert in the field. You all are the experts. If you have a question, I will make note of it but I will not be able to answer your questions.
	+ We would appreciate your attention for the next 75 minutes, please silence your mobile phones and other devices. If you must step away, feel free to do so and we will loop you back into the conversation when you return.
1. **Introductions (10 minutes)**
* First Name
* Location (City, State)
* Type of medical practice (size, specialty, patient population, health issues you see most often, and any emerging challenges)
* In thinking about how you stay updated on new clinical developments and guidelines, what digital or online resources do you use most frequently?
1. **Hepatitis C Screening/Testing Practices (5 minutes)**

**SHOW ONLINE VOTING TOOL:**  *Let’s begin by getting your reasons for testing patients for hepatitis C.* Please indicate whether you generally test for hepatitis C if the following factor is present.

|  |
| --- |
| In general, I test a patient for hepatitis C if this individual factor is present: Check all that apply.  |
| * Blood transfusion (before 1992)
* Elevated ALTs
* Tattoos
* History of any drug use
* Body piercings
* HIV
* Pregnancy
* Born from 1945-1965
* Multiple sexual partners
* History of injection drug use
* History of incarceration
* Man who has sex with other men
 | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |

* **SUMMARIZE AND EXPLORE RESPONSES in general.**

* **SUMMARIZE and explore responses specifically to people born from 1945-1965.** Do you typically test Baby Boomers (people born 1945-65)? Why or why not?
* **HANDCOUNT:** Has anyone had patients request to be tested for hepatitis C?
What prompted them to request testing?
1. **Hepatitis C Screening and Diagnosis (5 Minutes)**

**SHOW ONLINE VOTING TOOL:**  So let’s talk about how much hepatitis C you see in your practice. We will use the online screen again. In the last year, can you estimate how many of your patients tested positive for hepatitis C antibodies?

* 0
* 1-2
* 3-4
* 5-9
* 10-14
* 15-19
* 20-24
* More than 25
* Not sure or don’t remember
* **SHOW SCREEN, SUMMARIZE.**
* So among your patients who tested positive for hepatitis C antibodies, what was the impetus for testing them?
1. **PCPs ONLY: Proposal – Universal Screening (35 minutes)**

Current recommendations have not been sufficient for identifying all the people living with hepatitis C. As a result, CDC is considering a few different approaches to increase the number of people identified with hepatitis C. We’ll be showing you several different statements beginning with this one.

**ON SCREEN:***CDC Recommendation under consideration*:

Hepatitis C screening at least once in a lifetime for all adults aged 18 years and older

* What is your reaction to this recommendation? What do you think of testing all adults for hepatitis C?
* Nationally, about 1% of the US adult population is living with hepatitis C. I am now going to show you prevalence of current HCV infection, by the states where you live.
* **SHOW INFORMATION FROM TABLE 2: ONLY SHOW STATES IN WHICH PARTICIPANTS PRACTICE (BASED ON SCREENING)**

* What are your thoughts about this table? How do these numbers for your state compare with your experience?

Another potential approach is to recommend one-time hepatitis C antibody testing for all adults in settings where the prevalence of HCV infection is higher than 0.1%.

**ON SCREEN:***CDC Recommendation under consideration*:

Hepatitis C screening at least once in a lifetime for all adults aged 18 years and older, except in settings where the prevalence of HCV infection is less than 0.1%

* What is your reaction to this potential recommendation?
* Can you describe what information you have about the prevalence of hepatitis C infection in your practice?
	+ Probe: Is obtaining the prevalence of hepatitis C in your practice something you think you could find out about? Can you explain how you go about collecting or getting that information?
* Let’s look at some language around determining prevalence and then we will discuss it.

**ON SCREEN:***Determining prevalence in a clinic or other health care setting*:

In the absence of existing data for hepatitis C prevalence, health-care providers should initiate voluntary screening until they establish that the diagnostic yield is <1 per 1,000 patients screened, at which point such screening is no longer warranted.

* What are your thoughts on this aspect of the recommendation?
* Is getting this prevalence data feasible in your practice?

In addition to the universal testing recommendation for all adults, CDC would recommend everyone who has ongoing risk for HCV infection should be tested periodically for hepatitis C.

**ON SCREEN:***CDC Recommendation under consideration*:

*Regardless of age or setting prevalence, all persons with risk factors should be tested for hepatitis C, with periodic testing while risk factors persist.*

* What is your reaction? Can you describe your practice testing patients with risk factors?
* Probe: How do you go about deciding what interval to test your patients?
1. **PCPs ONLY: Rationale for CDC Hepatitis C Screening Recommendation (10 minutes)444**

Now, I want to show you some of the background and rationale for the new proposed screening guidelines. Please review the statements separately and then use the online tool to indicate if each statement is compelling to you as a rationale: 1 means “not at all compelling” and 5 means “very compelling.”

|  |  |  |  |
| --- | --- | --- | --- |
|  | Not at all compelling |  | Very compelling |
| Hepatitis C is the most common chronic blood-borne infection in the United States. | 1 | 2 | 3 | 4 | 5 |
| Approximately 10%–15% of adults with chronic HCV infection, will develop progressive liver fibrosis and cirrhosis. | 1 | 2 | 3 | 4 | 5 |
| Hepatitis C is the most common reason for liver transplantation in the United States. | 1 | 2 | 3 | 4 | 5 |
| Incidence of hepatitis C is greatest among persons of reproductive age (20–39 years). | 1 | 2 | 3 | 4 | 5 |
| 50% of people with hepatitis C are unaware of their infection  | 1 | 2 | 3 | 4 | 5 |
| Simple, well-tolerated oral medication regimens result in virologic cure in most people. | 1 | 2 | 3 | 4 | 5 |
| Treatment results in regression of cirrhosis, decreased risk of cancer, increased survival, and reduced transmission to others. | 1 | 2 | 3 | 4 | 5 |
| Identifying infections may result in stigma. | 1 | 2 | 3 | 4 | 5 |
| Limited risk of harms associated with diagnostic work-up and/or treatment for patients with hepatitis C. | 1 | 2 | 3 | 4 | 5 |
| The rate of acute HCV infection has more than doubled from 2011 through 2016, mostly among people of childbearing age.  | 1 | 2 | 3 | 4 | 5 |
| During 2010–2016, of all U.S. adults, 1.0% were viremic | 1 | 2 | 3 | 4 | 5 |

* What’s your overall reaction to these points? Are any of them more or less persuasive than others?
* Are there any points that were confusing or that you wanted more information or elaboration?
* Which, if any, of these points really stood out for you?
1. **OB/GYN ONLY: Proposal -Universal Screening During each Pregnancy (35 minutes)**

CDC is considering recommending universal hepatitis C antibody testing for all women during each pregnancy.

**ON SCREEN:***CDC Recommendation under consideration*:

*Hepatitis C screening for all pregnant women during each pregnancy*

* What is your reaction to this potential recommendation? What do you think of testing all pregnant women for hepatitis C?
* In 2015, of all live births, 0.38% were delivered by women testing positive for anti-HCV or HCV RNA. Now, I am now going to show a table of hepatitis C in women of childbearing age and infection by state and then we will discuss.

[only states where the participants practice will be shown]

Hepatitis C Virus in Women of Childbearing Age, Pregnant Women

|  |  |
| --- | --- |
|  **Birth certificate data**  |  **Laboratory data**  |
| **State**  | **Total births**  | **Births to HCV-infected women**  | **Infection rate per 100**  | **Rank**  | **Detection rate per 100**  | **Rank**  |
| West Virginia  | 19,783  | 550  | 2.78  | 1  | 2.40  | 2  |
| Kentucky  | 55,868  | 1,027  | 1.84  | 2  | 1.65  | 3  |
| Vermont  | 5,888  | 78  | 1.32  | 3  | 0.14  | 33a  |
| Montana  | 12,558  | 163  | 1.30  | 4  | 2.82  | 1a  |
| Tennessee  | 81,522  | 1,013  | 1.24  | 5  | 1.12  | 4  |
| Ohio  | 138,948  | 1,632  | 1.17  | 6  | 0.66  | 5  |
| Maine  | 12,581  | 141  | 1.12  | 7  | 0.12  | 37a  |
| New Hampshire  | 12,403  | 136  | 1.10  | 8  | 0.28  | 18  |
| North Dakota  | 11,306  | 121  | 1.07  | 9  | 0.32  | 15a  |
| Pennsylvania  | 139,334  | 1,242  | 0.89  | 10  | 0.38  | 13  |
| New Mexico  | 25,764  | 221  | 0.86  | 11  | 0.16  | 31  |
| Mass-achusetts  | 71,130  | 605  | 0.85  | 12  | 0.42  | 10  |
| Delaware  | 11,108  | 83  | 0.75  | 13  | 0.10  | 40  |
| Alaska  | 11,262  | 79  | 0.70  | 14  | 0.53  | 6  |
| Missouri  | 74,931  | 408  | 0.54  | 15  | 0.31  | 16  |
| Florida  | 223,570  | 1,041  | 0.47  | 16  | 0.46  | 8  |
| Rhode Island  | 10,881  | 50  | 0.46  | 17  | 0.00  | 51a  |
| Oklahoma  | 53,023  | 243  | 0.46  | 18  | 0.51  | 7a  |
| Indiana  | 83,864  | 359  | 0.43  | 19  | 0.45  | 9  |
| Oregon  | 45,539  | 184  | 0.40  | 20  | 0.14  | 35  |
| South Dakota  | 12,312  | 43  | 0.35  | 21  | 0.21  | 23a  |
| Louisiana  | 64,550  | 215  | 0.33  | 22  | 0.35  | 14  |
| Arkansas  | 38,804  | 125  | 0.32  | 23  | 0.23  | 22  |
| Maryland  | 73,322  | 233  | 0.32  | 24  | 0.28  | 19  |
| Washing-ton  | 88,745  | 280  | 0.32  | 25  | 0.10  | 39  |
| Michigan  | 113,060  | 329  | 0.29  | 26  | 0.28  | 20  |
| North Carolina  | 120,519  | 347  | 0.29  | 27  | 0.19  | 26  |
| South Carolina  | 57,985  | 166  | 0.29  | 28  | 0.14  | 34  |
| Virginia  | 102,980  | 291  | 0.28  | 29  | 0.16  | 30  |
| Alabama  | 59,550  | 163  | 0.27  | 30  | 0.20  | 25  |
| New York  | 232,941  | 592  | 0.25  | 31  | 0.10  | 41  |
| Wisconsin  | 66,758  | 141  | 0.21  | 32  | 0.39  | 12a  |
| Arizona  | 85,164  | 176  | 0.21  | 33  | 0.15  | 32  |
| Nevada  | 36,193  | 73  | 0.20  | 34  | 0.10  | 42  |
| Utah  | 50,702  | 100  | 0.20  | 35  | 0.16  | 29  |
| Wyoming  | 7,747  | 15  | 0.19  | 36  | 0.06  | 48  |
| Minnesota  | 69,648  | 132  | 0.19  | 37  | 0.20  | 24a  |
| Iowa  | 39,407  | 69  | 0.18  | 38  | 0.30  | 17a  |
| Colorado  | 66,411  | 110  | 0.17  | 39  | 0.11  | 38  |
| Idaho  | 22,782  | 35  | 0.15  | 40  | 0.07  | 47  |
| Illinois  | 157,651  | 217  | 0.14  | 41  | 0.08  | 46  |
| Kansas  | 39,100  | 52  | 0.13  | 42  | 0.08  | 45  |
| Mississippi  | 38,291  | 50  | 0.13  | 43  | 0.18  | 28  |
| Georgia  | 131,027  | 161  | 0.12  | 44  | 0.09  | 44  |
| Texas  | 402,485  | 444  | 0.11  | 45  | 0.12  | 36  |
| District of Columbia  | 9,525  | 10  | 0.10  | 46  | 0.40  | 11  |
| Nebraska  | 26,637  | 25  | 0.09  | 47  | 0.05  | 49a  |
| California  | 489,668  | 435  | 0.09  | 48  | 0.09  | 43  |
| Hawaii  | 18,346  | 12  | 0.07  | 49  | 0.00  | 50a  |
| New Jersey  | NA  | NA  | NA  | 50a  | 0.25  | 21  |
| Connecticut  | NA  | NA  | NA  | 51a  | 0.18  | 27  |
| All states  | 3,823,723  | 14,417  | 0.38  | 0.26  |

* What are your thoughts on this table? How do the numbers for your state compare with your experience?
* Another potential approach is to recommend hepatitis C testing for all pregnant women, during each pregnancy, in settings where the prevalence of HCV infection is higher than 0.1%.

**ON SCREEN:***CDC Recommendation under consideration*:

*Hepatitis C screening for all pregnant women during each pregnancy, except in settings where the prevalence of HCV infection among pregnant women is less than 0.1%.*

* What is your reaction to this potential recommendation?
* Do you have information about the prevalence of hepatitis C infection in your practice?
	+ Probe: Is obtaining the prevalence of hepatitis C something you think you could find out about? Can you explain how you go about collecting or getting that information?
	+ If none, how might you go about getting that information?
* We will take a look at the potential language around determining prevalence and then we will discuss.

**ON SCREEN:***Determining prevalence in a clinic or other health care setting*:

In the absence of existing data for hepatitis C prevalence, health-care providers should initiate voluntary screening until they establish that the diagnostic yield is <1 per 1,000 [pregnant] patients screened, at which point such screening is no longer warranted.

* What are your thoughts on this aspect of the recommendation?
* How could you implement this recommendation in your practice? What would it look like for you?
1. **OB/GYN ONLY: Rationale for CDC Hepatitis C Screening Recommendation (15 minutes)**

Now, I want to show you some of the background and rationale for the new proposed screening guidelines. Please review the statements separately and then use the online tool to indicate if each statement is compelling to you as a rationale: 1 means “not at all compelling” and 5 means “very compelling.”

|  |  |  |  |
| --- | --- | --- | --- |
|  | Not at all compelling |  | Very compelling |
| Hepatitis C is the most common chronic blood-borne infection in the United States. | 1 | 2 | 3 | 4 | 5 |
| Approximately 10%–15% of adults with chronic HCV infection, will develop progressive liver fibrosis and cirrhosis. | 1 | 2 | 3 | 4 | 5 |
| Hepatitis C is the most common reason for liver transplantation in the United States. | 1 | 2 | 3 | 4 | 5 |
| Incidence of hepatitis C is greatest among persons of reproductive age (20–39 years). | 1 | 2 | 3 | 4 | 5 |
| Perinatal transmission of hepatitis C occurs in 5.8% of pregnancies. | 1 | 2 | 3 | 4 | 5 |
| 50% of people with hepatitis C are unaware of their infection.  | 1 | 2 | 3 | 4 | 5 |
| Simple, well-tolerated oral medication regimens result in virologic cure in most people. | 1 | 2 | 3 | 4 | 5 |
| Women can be treated following pregnancy, reducing transmission risk to future children.  | 1 | 2 | 3 | 4 | 5 |
| Identifying hepatitis C infected pregnant women also identifies at-risk infants needing testing. | 1 | 2 | 3 | 4 | 5 |
| Treatment results in regression of cirrhosis, decreased risk of cancer, increased survival, and reduced transmission to others. | 1 | 2 | 3 | 4 | 5 |
| Identifying infections may result in stigma. | 1 | 2 | 3 | 4 | 5 |
| Limited risk of harms associated with diagnostic work-up and/or treatment for patients with hepatitis C. | 1 | 2 | 3 | 4 | 5 |
| The rate of acute HCV infection has more than doubled from 2011 through 2016, mostly among people of childbearing age.  | 1 | 2 | 3 | 4 | 5 |
| In 2015, of all live births, 0.38% were delivered by women testing positive for anti-HCV or HCV RNA. | 1 | 2 | 3 | 4 | 5 |
| Statistical modeling suggests that pregnant women lived 1.21 years longer and had a 16% lower HCV-attributable mortality with universal testing. Universal prenatal hepatitis C testing increased identification of neonates exposed to hepatitis C at birth from 44% to 92%. | 1 | 2 | 3 | 4 | 5 |
| Universal testing during pregnancy with no treatment reimbursement restrictions was found cost effective at a willingness-to-pay threshold of $50,000 when the prevalence of HCV RNA was at or above 0.03%-0.04%.  | 1 | 2 | 3 | 4 | 5 |

* What’s your overall reaction to these points? Are any of them more persuasive than others?
* Are there any that you need more information or elaboration?
* Which, if any of these points really stood out for you?
1. **Wrap Up (5 minutes)**

Before we wrap up, is there any feedback you would like to share with CDC about anything we discussed tonight?

Thank you.